AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in healthy late preterm and term infants. RSV infections cause about 80,000 hospitalizations in children and 500 deaths each year.
Roche Holding AG Chief Executive Officer Severin Schwan said in an interview with CNBC it could take at least a couple of weeks, if not months, for the United States to implement broad testing for coronavirus.
Pfizer beat Wall Street estimates for Q1 profit and slightly raised the company’s 2019 earnings forecast as the largest U.S. drugmaker reined in costs and recorded higher Ibrance and Prevnar sales.
One in 10 drugs sold in developing countries is fake or substandard, leading to tens of thousands of deaths with many of them of African children given ineffective treatments for pneumonia and malaria, health officials said.
Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.
India granted Pfizer Inc. a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the treatment out of reach of thousands in poorer nations.
Pfizer’s second-quarter 2017 revenue missed Wall Street estimates, hurt by falling demand for its blockbuster pneumonia vaccine Prevnar as well as older drugs.
AbbVie’s biologic therapy Humira for autoimmune disorders continues to dominate the sales landscape; Gilead’s once-daily hepatitis C treatment Harvoni in 2016 repeated its performance as the world’s second-best-selling prescription medicine.
Chinese regulators approved Pfizer Inc.’s blockbuster vaccine Prevenar 13, a breakthrough for the firm after it was forced to shut its vaccine business in China during 2015.
Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.